ADMA Biologics (ADMA) has just been added to both the Russell 2000 Defensive Index and the Russell 2000 Growth-Defensive Index, a move that can reshape how index funds and benchmark-focused investors treat the stock.

ADMA Biologics’ recent index additions come after a stretch of mixed price action, with a 1-day share price return of 2.35% and a 7-day share price return of 9.44% contrasting with a year-to-date share price decline of 48.77%. Over a 5-year period, a total shareholder return of more than 5x indicates that long term holders have still seen very large gains, and recent momentum appears to be rebuilding from a lower base.

If this kind of renewed attention has you looking beyond ADMA Biologics, it could be a good moment to scan other healthcare names benefiting from AI tailwinds using the 40 healthcare AI stocks

For ADMA Biologics, fresh index inclusion and a share price that has fallen 48.77% year to date set up a familiar tension: commit capital after this rebound, or wait in case the valuation offers an even cheaper entry next.

Most Popular Narrative: 48% Undervalued

Against ADMA Biologics' last close of $9.16, the most followed narrative points to a fair value of $17.60, framing the recent index move against a much higher long term target.

Commercial-scale implementation of the FDA-approved yield enhancement process is producing a 20%+ increase in bulk immunoglobulin output, expected to drive sustained gross margin expansion and higher net income starting in early 2026 and beyond.

There is a detailed playbook sitting behind that $17.60 figure. It leans on compounding revenue, fatter margins, and a richer earnings multiple working together. It may be worth examining which of those three contributes most to this fair value estimate.

Result: Fair Value of $17.60 (UNDERVALUED)

However, the ADMA Biologics narrative still hinges on a concentrated product portfolio and successful execution of its yield enhancement process, both of which could challenge those fair value assumptions.

Next Steps

If the optimism in this ADMA Biologics story stands out to you, take a moment to review the data, stress test the assumptions and see how those potential upsides line up with your own expectations by checking the 3 key rewards

Looking for more investment ideas beyond ADMA Biologics?

If ADMA Biologics has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to surface fresh opportunities before other investors catch on.

• Target potential mispricings by scanning for resilient companies that still trade at appealing valuations through the 45 high quality undervalued stocks.
• Prioritise stability by focusing on stocks that pair lower risk scores with dependable fundamentals using the 74 resilient stocks with low risk scores.
• Hunt for under-the-radar opportunities by filtering for quality businesses that have not yet reached the spotlight via the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.